Meeting coordination for a pharmaceutical or biotech CEO involves far more than finding an available time slot. It requires managing complex multi-party scheduling, ensuring appropriate preparation for each engagement, coordinating pre-read materials, managing post-meeting follow-up, and maintaining the communication infrastructure that makes every meeting productive.
A virtual executive assistant who handles this function well transforms the CEO’s meeting experience: from reactive and underprepared to structured, well-resourced, and strategically organized.
The Meeting Landscape for Pharmaceutical and Biotech CEOs
Pharmaceutical and biotech executives manage a meeting portfolio that spans several distinct categories, each with different coordination requirements.
Board and governance meetings: Quarterly board meetings, committee sessions, and special board interactions require the most intensive coordination. Board members are senior, time-constrained, and expect professional-grade preparation and materials management.
Regulatory preparation meetings: Internal preparation sessions before FDA interactions, protocol to agency meetings, and cross-functional regulatory reviews require coordination across multiple internal stakeholders with specific agenda requirements.
Clinical review meetings: Pipeline reviews, safety review committee sessions, clinical milestone reviews, and data monitoring committee preparations involve clinical, regulatory, and medical affairs stakeholders.
Investor meetings: From one-on-one investor calls to conference investor day presentations, investor meeting coordination requires speed, professionalism, and attention to relationship context.
Scientific advisory board meetings: SAB meetings involve external scientific advisors who are typically senior academics or industry experts whose time must be managed with particular respect.
Business development meetings: Partner discussions, licensing negotiations, and M&A diligence meetings have confidentiality requirements that add a layer of coordination complexity.
Leadership team meetings: Recurring internal meetings with the executive leadership team, including pipeline reviews, operational reviews, and strategic planning sessions.
A virtual EA who manages all of these meeting categories provides the CEO with a coherent, well-prepared meeting schedule rather than a fragmented series of individually managed interactions.
Pre-Meeting Coordination
The preparation work that precedes a meeting is as important as the meeting itself in pharmaceutical and biotech contexts. A virtual EA manages pre-meeting coordination systematically for every significant engagement.
Materials Distribution
For board meetings, investor day events, and SAB sessions, the EA manages the distribution of pre-read materials in advance: ensuring correct versions are distributed to the right recipients, tracking acknowledgment of receipt, and following up with any materials not yet confirmed received.
In pharmaceutical and biotech, this materials management function often involves confidentiality controls: ensuring materials are distributed only to parties who have signed appropriate confidentiality agreements and through secure channels appropriate for pharmaceutical document sensitivity.
Agenda Management
The EA prepares and circulates agendas in advance of major meetings, coordinating with functional leaders who are presenting or contributing to the agenda. This coordination function ensures the CEO is not managing the logistics of internal presentation scheduling.
For board meetings, the EA coordinates with the CFO, CSO, CMO, and other relevant leaders to collect presentations, review them for completeness, and ensure the board agenda covers all required topics without exceeding the allotted time.
Attendee Coordination
Managing who attends which meetings requires judgment in pharmaceutical and biotech. FDA meetings require specific attendee lists; SAB meetings require careful management of outside experts; investor meetings often require investor relations and legal team participation. The EA manages these attendee lists, coordinating logistics for each participant without fragmenting the coordination work across multiple people.
Briefing Document Preparation
The EA prepares briefing documents for the CEO before every significant external meeting: background on attendees, relevant history of the relationship, key topics anticipated, and any context the CEO needs to be fully effective in the meeting.
These briefings are typically concise (one to two pages) and organized for rapid pre-meeting review. The goal is a CEO who walks into every meeting with full situational awareness rather than relying on memory or scrambling to prepare at the last minute.
During and After Meeting Management
Meeting Support
For virtual meetings, the EA manages technical setup: ensuring the correct conferencing link is in the meeting invitation, testing that recording or transcription tools are configured if needed, and managing the meeting entry logistics for external participants.
For in-person meetings at the CEO’s location, the EA coordinates logistics: room booking, catering if appropriate, visitor management, and any presentation or materials setup required.
Action Item Capture and Follow-Up
Post-meeting follow-up is one of the most underinvested areas in pharmaceutical executive operations, and one where a virtual EA provides significant value. After every significant meeting, the EA captures action items, assigns them to responsible parties, and distributes a meeting summary to relevant attendees.
More importantly, the EA tracks action items to completion, following up with responsible parties and escalating to the CEO when commitments are at risk of being missed. This follow-up function ensures that meeting decisions translate into organizational action, not just good intentions.
Managing FDA and Regulatory Meetings
FDA meetings require specialized coordination beyond standard business meeting management. The EA’s role in FDA meeting coordination includes:
- Coordinating the meeting request logistics with the FDA’s meeting management system
- Managing the preparation timeline: regulatory teams typically require four to six weeks of preparation for major FDA interactions
- Coordinating the pre-meeting internal dry run, where the CEO and key team members rehearse the interaction
- Managing logistics for any team members traveling to the FDA’s facilities
- Distributing the FDA meeting briefing package to internal stakeholders
- Sending confirmation communications to the FDA contact and ensuring all required documentation is in order
This specialized regulatory meeting coordination is one of the most specific and valuable functions a pharmaceutical-experienced virtual EA provides.
According to McKinsey, pharmaceutical companies that invest in structured meeting preparation and follow-up processes demonstrate significantly better outcomes in both internal decision quality and external regulatory and investor interactions.
Investor Conference Meeting Management
Healthcare investor conferences present a unique meeting coordination challenge: dozens of investor meetings scheduled within a compressed two to three day window, often at multiple venues within a single conference location.
The EA manages investor conference scheduling through the conference’s meeting scheduling platform, coordinating with investors and analysts to fill the CEO’s dance card while ensuring the highest-priority relationships are accommodated. They prepare a consolidated meeting schedule with investor background briefs, build in appropriate buffer time between meetings, and manage last-minute scheduling changes on the day of the conference.
For more on how virtual EAs handle the full spectrum of pharmaceutical executive support functions, benefits of EA for pharma covers the comprehensive value case. For executives ready to evaluate specific service options, best virtual EA for pharma provides a current market comparison.
Building a Meeting Coordination Operating Model
The most effective pharmaceutical CEO-EA pairs build a defined meeting coordination operating model that specifies:
- How far in advance the EA schedules different meeting categories
- What preparation each meeting category requires and who is responsible for providing input
- How action items are captured, distributed, and tracked
- What level of post-meeting communication the EA manages independently
This operating model converts meeting coordination from a reactive task into a structured function that runs consistently regardless of how busy any given week is.
Conclusion
Meeting coordination for pharmaceutical and biotech CEOs is a sophisticated operational function that spans pre-meeting preparation, in-meeting logistics, and post-meeting follow-up across multiple meeting types with different requirements and stakeholders. A virtual EA who manages this function well transforms the CEO’s meeting experience and organizational meeting quality simultaneously.
In an industry where the quality of regulatory interactions, investor relationships, and board engagement directly influences company outcomes, professional meeting coordination is not administrative overhead. It is organizational investment.
Related Reading
For further context, explore Virtual EA Meeting Coordination for Automotive CEOs and Virtual EA Meeting Coordination for Construction & Architecture CEOs.